GW&K Investment Management LLC Has $15.12 Million Stake in Charles River Laboratories International, Inc. $CRL

GW&K Investment Management LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.4% in the third quarter, Holdings Channel reports. The institutional investor owned 96,654 shares of the medical research company’s stock after purchasing an additional 8,341 shares during the period. GW&K Investment Management LLC’s holdings in Charles River Laboratories International were worth $15,122,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Rothschild Investment LLC raised its stake in shares of Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $29,000. Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International in the third quarter valued at about $31,000. Geneos Wealth Management Inc. boosted its stake in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after buying an additional 145 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in Charles River Laboratories International by 172.7% in the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after buying an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 3.4%

Shares of NYSE CRL opened at $175.08 on Friday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The firm has a market capitalization of $8.62 billion, a P/E ratio of -59.15, a P/E/G ratio of 3.10 and a beta of 1.64. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. The company’s 50 day simple moving average is $195.31 and its 200 day simple moving average is $180.72.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CRL. UBS Group raised their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Argus set a $200.00 price target on Charles River Laboratories International in a research report on Monday, November 17th. Mizuho dropped their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a report on Friday, February 20th. Weiss Ratings reissued a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Finally, Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a research note on Monday, December 1st. Ten analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.